ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2020 Congress

July 12-14, 2020. Virtual Congress.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Abstract Number: PB2286

    Radiological Parameters on Computed Tomography Pulmonary Angiography Correlate Poorly with Early Mortality from Acute Pulmonary Embolism

    I. Wu1, P.I. Ngam2, C.C. Ong2, W. Kristanto3, P. Kojodjojo3, L. Teo2, Y.L. Chee1, W.Y. Jen1

  • Abstract Number: PB1160

    Raising Factor VIII’s Half-life to the Next Level

    S. Kistner1, J. Daufenbach1, P. Herbener1, J. Schüttrumpf2

  • Abstract Number: PB1360

    Randomized Study for the Treatment of Primary Immune Thrombocytopenic Purpura (pITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone versus High-dose Dexamethasone. Preliminary Results. GIMEMA Protocol ITP0207

    M.G. Mazzucconi1, F. Paoloni2, A. Sau3, N. Vianelli4, I. Vincelli5, M. Ruggeri6, E. Rivolti7, L. Gugliotta7, G. Gaidano8, M. Napolitano9, N. Cascavilla10, C. Carbone11, V. Pavone12, V. De Stefano13, G. Avvisati14, M. Iodice2, E. Baldacci1, P. Fazi2, F. Rodeghiero6, C. Santoro1

  • Abstract Number: PB1618

    Rap1a/b Isoforms Differentially Regulate Megakaryocyte Biology

    D. Ghalloussi1, G. Harousseau1, A. Eckly2, J.P. Kenny1, C. Kirkpatrick1, E.C. O'Shaughnessy3, K. Hahn3, C. Gachet2, L. Stefanini4, K. Eto5, W. Bergmeier1

  • Abstract Number: PB1064

    Rapid Desensitization and Subsequent Immune Tolerance Induction in a Patient with Hypersensitivity and Inhibitor to Factor VIII

    W. Mitchell

  • Abstract Number: PB0686

    Rapid Latex Enhanced Immunoassay (LIA) for Heparin Induced Thrombocytopenia and False Positivity

    D. Welder1, F. Compton1, N. De Simone1, S. Nagalla2, S. Rambally2, C. Webb1, R. Sarode1,2

  • Abstract Number: PB0307

    Rapid Thaw Plasma Units Thaw Significantly Faster than Standard Plasma Units while Retaining Similar Coagulation Profile over 5 Days of Cold Storage

    K.M. Madden1, J.S. Raval1, L. Rosenbaum1,2, C. Richards3, C. Jones3, P. Lowery3, M.A. Rollins-Raval1

  • Abstract Number: PB0207

    Rare Bleeding Disorders in North India – Study from a Tertiary Care Centre

    S. Langer1, D. Gupta1, P. Sachdeva2, M. Kalra2, A. Sachdeva2, A. Sharma3, J. Kotwal1

  • Abstract Number: PB1167

    Rare Bleeding Disorders in Southern Iran: Revisited and Updated Data

    M. Bordbar1, M. Karimi1, A. Shahsavani1,2, S. Haghpanah1

  • Abstract Number: PB0176

    Rare Coagulation Disorders in Children – Is it Like to Buy a Pig in a Poke or Nothing Special? Experience of Saint Petersburg, Russia

    N. Sokolova, N. Vaynyunskaya

  • Abstract Number: PB2059

    Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care – Results from the Dresden NOAC Registry

    J. Beyer-Westendorf, S. Marten, L. Tittl, C. Naue

  • Abstract Number: PB2050

    Ratio of Inhibited Thrombin Generation Based on Dilute Prothrombin Time May Predict the Major Bleeding or Thrombotic Tendency in NVAF Patients Treated with Anti-Xa DOAC

    K. Ohmura1, M. Ieko1, S. Naito2, M. Yoshida2, N. Takahashi1, S. Ono3, I. Sakuma4

  • Abstract Number: PB0120

    Rationale and Design for the Study Apixaban versus ClopidoGRel on a Background of Aspirin in Patients Undergoing InfraPoPliteal Angioplasty for Critical Limb Ischemia – AGRIPPA Trial

    R. Biagioni1, R. Lopes2, L. Agati3, E. Ramacciotti4,5

  • Abstract Number: PB0910

    Rationale and Study Design for a Prospective, Low-Interventional Study to Investigate whether Systematic Joint Examination Impacts Haemophilia Treatment Management Decisions in Patients with Haemophilia A in France: The A-MOVE Study

    Y. Repessé1, J. Courias2, C. Gandossi2

  • Abstract Number: PB2371

    Real Life Experience of an Antithrombotic Stewardship Program for Thrombosis Prophylaxis during Hospitalisation in a Large Teaching Hospital

    M. Taskopru1, M. Slijkhuis2, S. van Wissen3, N. Khorsand4

  • Abstract Number: PB0785

    Real Life Experienceon 61 Acquired Haemophilia A (AHA) Patients from a Single Center

    M. Porrazzo, A. Ferretti, E. Baldacci, S. Aprile, F. Barone, R. Abbruzzese, A. Chistolini, M.G. Mazzucconi, C. Santoro

  • Abstract Number: PB0877

    Real Life Use of Emicizumab in Pediatric Patients without Inhibitors

    S.I. Heine, N. Graf

  • Abstract Number: PB0935

    Real World Efficacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database

    C. Wall1, H. Xiang2, B. Palmer2, P. Collins3, D. Hart4, G. Hall5, E. Chalmers6, G. Benson7, G. Evans8, R. Liesner9, M. Makris10, C. Harrison10, S. Mangles11, R. Maclean10, S. Shapiro12, D. Stephensen8, P. Sartain13, C. Hay2

  • Abstract Number: PB1591

    Real World Experience of Major Surgery and Delivery in Von Willebrand Disease

    B. Craven1, M.R. Peralta2, A. Riddell2, T.T. Yee2

  • Abstract Number: PB0796

    Real World Experience on Use of Susoctocog-alfa (rpFVIII) in the Treatment of a Population of Italian Elderly Patients with Acquired Haemophilia A

    E. Zanon1, S. Pasca1, A. Borchiellini2, C. Lodigiani3, A.C. Molinari4, P. Moscatelli5, C. Ambaglio6, P.S. Preti6, P. Simioni7

  • Abstract Number: PB1072

    Real World Experience with Rurioctocog Alfa Pegol in Vall d´Hebron University Hospital

    G. Robayo Buitrago1, J.C. Juarez2, O. Benitez1, M.F. Martinez1, M. Suito3, E. Alvarez1, M. Gironella4, F. Bosch4

  • Abstract Number: PB0349

    Real-life Inter-individual Variability of Pharmacokinetics – Reason for Individualization of Replacement Therapy in Haemophilia

    A. Traila1, C.E. Ursu2, D. Savescu2, F. Horhat3, M. Chincesan4, J.M.J. Patrascu3, C. Jinca3, M. Serban2, W. Schramm5, S. Arghirescu3

  • Abstract Number: PB1550

    Real-life Management of Digestive Endoscopies: Is There a Bleeding Risk for Patients with von Willebrand Disease?

    V. Horvais1, B. Guillet2, P. Beurrier3, V. Cussac4, B. Pan-Petesch5, N. Baty3, S. Cochennec2, G. Drugmanne5, S. Bayart2, J. Rose4, F. Nedelec-Gac2, N. Drillaud1, M. Sigaud1, M. Fouassier1, C. Ternisien1, M. Trossaert1, the BERHLINGO Group

  • Abstract Number: PB0148

    Real-time in vivo Visualization of Infused FVIIa in Hemophilia A Mice Following Injury

    J.C. Small1, T.J. Stalker2, L. Dankner1, S.M. Zintner1, P. Margaritis2

  • Abstract Number: PB0655

    Real-time Intra-site and Multi-site Correlations and Evaluation of Time Stability with the Same Frozen Plasmas Kits which Cover the Full Measuring Range for Routine Tests and Anticoagulant Monitoring Tests

    C. Flaujac1, I. Amouroux2, P. Manzi1, S. Doan1, L. Germain2, J. Dieu2, S. Pinheiro Vaz1, P. Plu1, E. Saksik1, S. Zia-Chahabi1

  • Abstract Number: PB0340

    Real-world Analysis of Hemophilia Patients in China: A Single Center’s Experience

    X. Song, F. Xue, L. Zhang, Y. Yang, R. Yang

  • Abstract Number: PB0873

    Real-World Cost of Emicizumab

    A.L. Dunn1,2, N. Toocheck3, M. Hallam1, C. Soller4, M. Storey5

  • Abstract Number: PB0948

    Real-World Data of First-Time and Rescue Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein in Patients with Hemophilia A with Inhibitors in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 2 Interim Analysis

    M. Taki1, K. Nogami2, C. Nagae1, A. Nagao3, K. Moritani4, K. Koh5, M. Shiraishi6, M. Takatoku6, M. Shima2

  • Abstract Number: PB0879

    Real-World Effectiveness Evaluation of the Recombinant Factor VIII Fc Fusion Protein in Adolescents and Children with Hemophilia A in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 1 Interim Analysis

    M. Kobayashi1, T. Matsushita2, K. Nogami3, I. Usami4, M. Shiraishi5, M. Takatoku5

  • Abstract Number: PB1051

    Real-world Evidence on the Use of rIX-FP in Patients with Hemophilia B: Interim Results from Three Multinational Prospective, Non-interventional, Post-market Surveillance Studies

    A. Tagliaferri1, J. Oldenburg2, K. Peerlinck3, G. Castaman4

  • Abstract Number: PB0980

    Real-World Experience of rVIII-SingleChain Treatment in a French Single Center

    A.A. Hassoun

  • Abstract Number: PB0928

    Real-World Experience with Emicizumab in Persons with Hemophilia A (HA) with or without Inhibitors

    M. Lewandowska, N. Randall, J. Maahs, N. Bakeer, J. Sagar, A. Greist, A. Shapiro

  • Abstract Number: PB0919

    Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States

    S.X. Sun1, S. Milligan2

  • Abstract Number: PB0779

    Real-World Use of Recombinant B-Domain-Deleted, Porcine-Sequence Factor VIII in Patients with Acquired Hemophilia A: An Interim Analysis of the Post-Authorization Safety Study in the European Union (EU)

    W. Miesbach1, C. Ambaglio2, P. Knoebl3, C. Lodigiani4, R. Santoro5, J. Chen6, N. Tripkovic7, R. Klamroth8

  • Abstract Number: PB2394

    Reasons and Associated Outcomes in Delayed Anticoagulation in Venous Thromboembolism

    N.E. Brunton1, W.E. Wysokinski2, D.O. Hodges3, D.T. Vlazny2, D.E. Houghton2, A. Casanegra4

  • Abstract Number: PB2511

    Reassessment of Venous Thromboembolism Risk and Prophylaxis in Post-Delivery Period of Healthy Women

    A. Braester1,2, J. Borenstein2,3, A. Zverev3, E. Kukuyev4, E. Shaoul4, G. Stemer5, M. Barhoum4,6

  • Abstract Number: PB2208

    Recanalization of Venous Thrombosis by Robotic Assisted High Frequency Pulsed Cavitational Ultrasound Therapy: 2 Weeks Follow-up in a Swine Model

    L. Khider1,2, G. Goudot1, C. Del Giudice3, T. Mirault1, A. Galloula1, P. Bruneval4, M. Tanter2, M. Pernot2, E. Messas1

  • Abstract Number: PB1545

    Recombinant Human von Willebrand Factor (rVWF) Differs in Structure and Function from Plasma Derived Concentrates

    H. Gritsch1, G. Schrenk1, N. Weinhappl1, B. Mellgård2, B. Ewenstein2, F. Truong Berthoz3, P.L. Turecek1

  • Abstract Number: PB1558

    Recombinant von Willebrand Factor (rVWF) in Patients with von Willebrand Disease (VWD) Undergoing Elective or Emergency Surgery in Real World Setting – The Dijon University Hospital Experience from March 2019 to January 2020

    F. Genre Volot1, A. Callegarin2, E. de Maistre2

  • Abstract Number: PB1224

    Recommendation on the Treatment of Venous Thromboembolism in Cancer Patients at a Brazilian Public Oncological Institution: Educational Plan

    C. Rothschild1, N. De L. Nedach2, A. P. Rabelo3, P. R. Souza3, G. B.G. Faria3, M.R.S. Maria R. Silva4, A. A.G.S. Brandão1, M.D.P. E. Diz5, J. Pereira6, V. Rocha6

  • Abstract Number: PB2328

    Recovery from Acute Kidney Injury in Patients with Pulmonary Embolism: A Monocenter Study

    M. Murgier1, L. Fouillet1, E. Ollier1, A. Merah1, N. Moulin1, S. Accassat1, C. Duvillard1, E. De Magalhaes1, P. Mismetti1, M. Monreal2, L. Bertoletti1

  • Abstract Number: PB1937

    Recurrence of Thrombotic Events in Antiphospholipid Syndrome Patients Receiving Prolonged Vitamin K Antagonists Therapy

    M. Sousa, G. Oliveira, C. Koch

  • Abstract Number: PB0397

    Red Blood Cells Support Factor X Activation via Intrinsic Tenase

    I.A. Chabin1,2, N.A. Podoplelova1,3, F.I. Ataullakhanov1,3,4, M.A. Panteleev1,3,4

  • Abstract Number: PB1963

    Redox Regulation of Neutrophil Mac-1 Function by Protein Disulphide Isomerase

    A. Dupuy1,2, S. Oehlers1,3, L. Hagimola1, C. Gomez1, S. Zheng2, P. Hogg1,3, J. Chiu1,3, F. Passam1,2,4

  • Abstract Number: PB2041

    Reduced Bleeding After an Intervention to Limit Excess Aspirin Use Among Patients on Chronic Warfarin

    J.K. Schaefer1, J. Errickson2, X. Gu3, T. Alexandris-Souphis3, M.A. Ali4, B. Haymart3, S. Kaatz5, E. Kline-Rogers3, J.H. Kozlowski6, G.D. Krol5, V. Shah5, S.L. Sood7, J.B. Froehlich3, G.D. Barnes3

  • Abstract Number: PB1532

    Reduced Cleavage of Circulating Ultra-large von Willebrand Factor by ADAMTS13 Exacerbates Microvascular Disease Following Traumatic Injury

    W. Plautz1, S. Haldeman2, M. Dyer2, M. Neal2

  • Abstract Number: PB1642

    Reduced GPVI Signalling in Genetic and Disease Models of Thrombocytopenia

    S.R. Hyslop1,2, M. Lebois1,2, J. Corbin2, P. Gangatirkar2, K.D. Sutherland1,2, R.K. Andrews3, E.E. Gardiner4, W.S. Alexander1,5, E.C. Josefsson1,2

  • Abstract Number: PB0834

    Reduced Splenic T Cells Count in an Untreated Mouse Model of Severe Hemophilia A

    C. Borsotti, V. Kalandadze, I. Mohammed, P. Di Simone, A. Follenzi

  • Abstract Number: OC 01.4

    Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression

    M. Lenz1, C. Kaun1, A. Rehberger2, M. Sebestjen2, C. Binder3, K. Huber4, C. Hengstenberg1, J. Wojta1, W. Speidl1, P. Hohensinner1

  • Abstract Number: PB2548

    Reduction of Thromboembolic Disorders in Pregnancy and Postpartum Period: Role of National Pregnancy Heart Team

    I. Davydova1,2, S. Siromakha3, A. Rusnak4, A. Ogorodnyk1, V. Lazoryshynets5

  • Abstract Number: PB/CO18

    Reduction of Venous Thromboembolic Events in Hospitalized Patients with Coronavirus Disease 2019 after Intensification of Thromboprophylaxis

    P. Filippidis1, E. Kampouri1, B. Viala1, M. Méan1, O. Pantet1, F. Desgranges1, J. Tschopp1, J. Regina1, E. Karachalias2, C. Bianchi1, M. Zermatten1, K. Jaton1, S.D. Qanadli1, P.-A. Bart1, J.-L. Pagani1, B. Guery1, M. Papadimitriou-Olivgeris1, L. Alberio1

  • Abstract Number: PB1743

    Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets

    I. Krueger1, H. Bock2, M. Elvers1

  • Abstract Number: PB2568

    Reference Ranges for Hemostasis Parameters during ¨Pregnancy and Puerperium

    V. Potylitsina1,2, Y. Raspopin1,2, I. Olkhovsky3,4, P. Toulon5

  • Abstract Number: PB1032

    Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia

    J. St-Louis1, A. Abad2, S. Akins3, S. Austin4, P. Chowdary5, S. Classey4, S. Funk6, G. Hernandez7, P. Hilliard2, M. Manco-Johnson6, S. Mangles8, P. McLaughlin5, D. Nugent7, A. Shapiro3, A. Srivastava9, M. Tilak9, A. Wells8, N. Zourikian1, V. Blanchette2, B.M. Feldman2

  • Abstract Number: PB0601

    Reference Values of 117 Healthy Donors on the ST Genesia with the STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen Reagents

    M. Ninivaggi1, R. de Laat-Kremers1, A. Carlo2, B. de Laat1

  • Abstract Number: PB1442

    Refractory Thrombocytopenia with TUBB1 Variants: Clinical Features and Responses to Eltrombopag Treatment

    M. Jiang1, G. Sheng2, J. Yin2, X. Wang2, Z. Yu2, C. Ruan2

  • Abstract Number: PB1865

    Relapsing or Refractory Thrombotic Microangiopathies: The Key Role of ADAMTS13 Activity and Complement Testing

    E. Gavriilaki1, E.-E. Koravou1, T. Chatzikonstantinou1, C. Kalpadaki2, N. Printza3, M. Ximeri2, A. Christoforidou4, G. Karavalakis5, I. Tassi6, M. Tzellou7, A. Spyridonidis8, E. Kapsali6, K. Kollios7, E. Mandala9, E. Vlachaki10, P. Tsirigotis11, E. Papadaki2, C. Lalayanni1, I. Sakellari1, A. Anagnostopoulos1, Thrombotic Microangiopathy Study Group

  • Abstract Number: PB2239

    Relation between the von Willebrand Factor and ADAMTS13 with Venous Thrombosis Risk. Results from the Retrove Project

    D. Llobet1, C. Vallvé1, A. Oliver2, M. Carrasco1, N. Vilalta1, J. Mateo1, J.C. Souto1

  • Abstract Number: PB0042

    Relationship between Distal Venous Thrombosis and Asymptomatic Atherosclerotic Disease

    A. Adamo, L. Spiezia, F. Dalla Valle, G. Avruscio, P. Simioni

  • Abstract Number: PB1787

    Relationship between HAART treatment and Markers of Coagulation among People Living with HIV/AIDS (PLWHA) in Gombe, Nigeria

    S. Adamu1,2, G. Aglavdawa3, S.A. Ufelle4, S. Yuguda3,5, A.I. Girei3,5, Y.M. Sherrif3

  • Abstract Number: PB1333

    Relationship between Platelet Function and Glycome Composition in Immune Thrombocytopenia

    E. Monzon Manzano1, P. Acuña1, M.T. Álvarez Román1, M. Martín Salces1, M.I. Rivas Pollmar1, I. Fernández Bello1, V. Jiménez Yuste1,2, N. Butta1

  • Abstract Number: PB2042

    Relationship between TTR and Daily Vitamin K Intake in Patients Taking Warfarin: The Difference among VKORC1 Genotype

    T. Nagao1, K. Yasunishi2, H. Kumagai2, E. Kodani3, K. Kimura4

  • Abstract Number: PB2066

    Relationship of Health Literacy and Adherence to Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation in Brazil

    F. Bartolazzi1, A.L.P. Ribeiro1, W.J.F.N. Sousa1, J.L.P. Silva2, M.S. Vianna3, M.F.d.S. Praxedes4, M.A.P. Martins1,3

  • Abstract Number: PB2338

    Relevance of Immobility as Deep Vein Thrombosis Risk Factor for Medically Ill Patients

    M. Sartori, E. Favaretto, B. Cosmi

  • Abstract Number: PB0265

    Relevance of Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 p.Thr309Lys Variant

    M.E. de la Morena-Barrio1, R. Lopez-Galvez1, A. Miñano1, V. Vicente1, J. Emsley2, J. Corral1, A. Lopez-Lera3

  • Abstract Number: PB2234

    Relevance of Thrombophilia Screening in Adult Renal Transplant Recipients

    D. Bahri1, H. Baccouche1, L. Ben Fatma2, S. Hadded2, A. Chakroun1, S. Mahjoub1, M.K. Zouaghi2, N. Ben Romdhane1

  • Abstract Number: PB0145

    Reported Values and Methodologies for Detecting Plasma D-dimer in Rat Models: A Systematic Review and Meta-analysis

    J. Chung1,2, S. Afraz2,3, D. Matino2,4, A. Chan2,3,4

  • Abstract Number: PB1156

    Rescue of the Endogenous FVIII Expression in Hemophilia A Mice Using CRISPR/Cas9 Gene Editing

    C.-Y. Chen1, X. Cai1, C. Miao1,2

  • Abstract Number: PB0882

    Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial

    S.S. Trakymienė1, C. Shen2, S. Benchikh El Fegoun3, A. Landorph2

  • Abstract Number: PB1363

    Response Rate and Response Duration after Discontinuation of Treatment with Thrombopoietin Receptor Agonists (TPO-RAS) in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study. Preliminary Results. GIMEMA Protocol ITP0714

    M.G. Mazzucconi1, F. Paoloni2, M. Carpenedo3, V. De Stefano4, S. Cantoni5, N. Vianelli6, M. Iodice2, E. Baldacci1, F. Zaja7, A. Bosi8, P. Schinco9, P. Fazi2, F. Rodeghiero10, C. Santoro1

  • Abstract Number: PB1349

    Response to Avatrombopag (AVA) in Chronic Immune Thrombocytopenia: Alternative Efficacy Measures

    H. Maitland1, K. Aggarwal2, M. Vredenburg2, W. Tian2, N. Gabrail3

  • Abstract Number: PB1571

    Response to Desmopressin Acetate in Von Willebrand Disease Type 2

    G.A. Maia1,2, S.D.S. Freitas1, P.S.R. Cardoso1,3, L.C. Oliveira4, D.G. Chaves3, S.M. Rezende1

  • Abstract Number: PB1549

    Response to Treatment for Gastro-Intestinal Bleeding in von Willebrand Disease

    E. Biguzzi1, S.M. Siboni1, R. Gualtierotti2, S. Braham1, M.T. Pagliari3, F. Peyvandi3,4

  • Abstract Number: PB1169

    Results from a Phase 4, Real-World Study Confirm the Safety and Effectiveness of rFXIII-A2 for the Treatment of Congenital FXIII A-Subunit Deficiency

    L. Hvitfeldt Poulsen1, B.A. Kerlin2, G. Castaman3, A.C. Molinari4, M. Menegatti5, S. Dey6, M.-L. Garly7, M. Carcao8

  • Abstract Number: PB2213

    Results of a Dedicated Diagnostic Work-up of Patients with Post-PE Syndrome

    G.J.A.M. Boon1, S.M.J. Janssen2, H.J. Bogaard3, L.J.M. Kroft4, L.J. Meijboom5, M.K. Ninaber6, E.J. Nossent7, P. Symersky8, H.W. Vliegen9, A. Vonk Noordegraaf7, M.V. Huisman1, J.J. Abbink2, F.A. Klok1

  • Abstract Number: PB0653

    Results of Anti-Xa Activities for Monitoring Therapeutic and Prophylactic Doses of Low Molecular Weight Heparin in Children

    J. Obuljen1, G. Jakovljević2, S. Margetić3, I. Linarić1, J. Leniček Krleža1

  • Abstract Number: PB2332

    Retinal Vein Thrombosis and the Association with Inherited Thrombophilia, Cardiovascular Risk Factors and the Risk of Occult Cancer. a Prospective Study

    D. Tormene1, G. Turatti1, C. Simion1, M. Marobin2, S. Gavasso1, E. Campello1, P. Simioni1

  • Abstract Number: PB1237

    Retrospective Analysis of Characteristics and Outcomes of 340 Pediatric ITP Patients in One Center

    R. Li1, R. Yang2

  • Abstract Number: PB1555

    Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: Study Design and Initial Demographic Results

    J.C. Roberts1, M. Escobar2, S. Acharya3, N.X. Hwang4, M. Wang5, S.A. Hale6, A. Oladapo6, S. Asghar7, P.A. Kouides8

  • Abstract Number: PB1870

    Retrospective Study of 30 TTP Patients from 2017 to 2019 in a Single Center of Suzhou, China

    J. Yin, Z. Yu, Z. Wang, D. Kong, J. Su, M. Jiang, C. Ruan

  • Abstract Number: PB2438

    Retrospective Study of Patients with Upper Extremity Clots Presenting to Emergency Departments in Tertiary Care Hospitals in a Major Canadian City in the Last Five Years

    T. Pannu1, E. Herget2, D. Suryanarayan1

  • Abstract Number: PB0317

    Reversal of Dabigatran by Idarucizumab in Heart Transplantation Surgery: A Case Report

    F. Robles de Vasconcelos, C. Vaz, L. Ricca Gonçalves, C. Monteiro, D. Aranda, M.C. Koch

  • Abstract Number: PB1112

    Reversal of Direct Oral Anticoagulants with Three-Factor Prothrombin Complex Concentrate: Real World Experience from a Tertiary Centre in Hong Kong

    S.Y. Kong, S.F. Yip, C.Y. Ha

  • Abstract Number: PB0306

    Reversal of Heparin Anticoagulation by Andexanet Alfa (Andexanet) in Human Plasma and Whole Blood: Differential Effect of Andexanet on Antithrombin-Dependent Anticoagulants and Direct Thrombin Inhibitors (DTIs)

    G. Lu, K. Bui, J.T. Curnutte, P.B. Conley

  • Abstract Number: PB1069

    rFIXFc at Lower Doses Can Achieve Very Significant Reduction of Annualized Bleed Rates in Children with Severe Haemophilia B

    A. Abraham1, F. N.A2, R.G. Dave3, S.C. Nair3, A.S. Singh2, U.P. Kulkarni2, A.J. Devasia2, A. Korula2, K. M L2, B. George2, V. Mathews2, A. Srivastava2

  • Abstract Number: PB1061

    rFVIIIFc at Lower Doses Can Achieve Clinically Meaningful Reduction of Annualized Bleed Rates in Children with Severe Haemophilia A

    A. Abraham1, F. N.A1, T. Geevar2, S.C. Nair2, A.S. Singh1, U.P. Kulkarni1, A.J. Devasia1, A. Korula1, K. M L1, B. George1, V. Mathews1, A. Srivastava1

  • Abstract Number: PB1277

    Right Atrial Thrombosis in Children: Patient Characteristics, Outcomes, and Interrater Reliability of Echocardiographic Characterization

    B.T. Barnes1, W. Ravekes1, G. Freire2, E. Amankwah3,4, J. Chiu5, A.R. Sellers6,7, D. Procaccini1,8, C.M. Takemoto9,10, N. Goldenberg6,9,11

  • Abstract Number: PB2302

    Right Ventricular to Left Ventricular Diameter Ratio Assessment with Non-ECG Gated Computed Tomography Scans and its Correlation with Right Ventricular Dysfunction in Acute Pulmonary Embolism

    J. Bilbao1, J. Bonorino1, H. Fernandez1, C. Ferrario2, K. Palacio2, R. Melchiori1, P. Colimodio3, P. Alarcon1, N. Torres1, M. Iwanowski1, J. Santucci1, E. Ortis1, S. Krause1, R. Della Cella1, N. Perez Caceres1, A. Sanchez1, S. Marquez1, P. Rubio1, S. Baratta1, A. Hita1

  • Abstract Number: PB2350

    Risk Factors and Frequency of Recurrent Long-Term Venous Thromboembolism After Superficial Vein Thrombosis of The Lower Limbs

    K.M. Nikolakopoulos, S. Kakkos, C.P. Papageorgopoulou, I. Ntouvas, S. Papadoulas, A. Kouri, P. Tsantrizos

  • Abstract Number: PB2306

    Risk Factors and Hemostatic Aspects of Aseptic Cerebral Venous Sinus Thrombosis

    K. Stepanchenko1, V. Marchenko1, A. Zhidkova2, T. Donnik2, I. Feday2

  • Abstract Number: PB2316

    Risk Factors and Patterns of Lower Limb Deep Venous Thrombosis in Gombe, North-Eastern Nigeria

    S. Yuguda1,2, A.I. Girei1,2, K.M. Pindiga2, R.A. Dachi3, A.U. Usman4,5, H.U. Faoruk6,7, A. Saidu8

  • Abstract Number: PB1878

    Risk Factors Associated with Severe Neurological Symptoms in Thrombotic Thrombocytopenic Purpura (TTP)

    J.T.S. Castro1, B.D.M. Mazetto2, A.P. Rosa2, G. Yamagutti2, E.V. Paulo3, J.A. Bizachi3, F. Reis1, F.A. Orsi3

  • Abstract Number: PB2539

    Risk Factors for Severe Preeclampsia in Obstetric Antiphospholipid Syndrome (OAPS) with Conventional Treatment

    G. de Larrañaga1, O. Latino2, S. Udry1, S. Perés Wingeyer1, F. Aranda1, V. Lara1, D.S. Fernández Romero2

  • Abstract Number: PB1308

    Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

    D. Evstratov1, P. Zharkov2, N. Myakova1

  • Abstract Number: PB1307

    Risk Factors for the Development of Hospital-acquired Pediatric Thromboembolism – Dealing with Potentially Causal and Confounding Risk Factors Using Direct Acyclic Graph (DAG) Analysis

    L. R. Campos1,2, M. Petroli1,3, F. R Sztajnbok1,4, E.S. Costa1, L. R Brandao5, M. G. P. Land1,6

  • Abstract Number: OC 12.4

    Risk Factors for Venous and Arterial Thrombosis in the Neonatal Intensive Care Unit (NICU)-A Multicenter Case Control Analysis

    R. Bhat1, S. Kwon2, I. Zaniletti3, K. Murthy4, R. Liem1

  • Abstract Number: PB2426

    Risk Factors of Hemorrhagic Complications on the Anticoagulant Therapy

    N. Vorobyeva1, A. Schapkov2

  • Abstract Number: PB2312

    Risk Factors of Thrombotic Complications in Thai Thalassemia Patients

    N. Hantrakun, T. Kunlayawutipong, L. Norasetthada, A. Tantiworawit, E. Rattaritamrong, T. Rattanathammethee, S. Huntrakool, P. Piriyakhuntorn, C. Chai-Adisaksopha

  • Abstract Number: PB2107

    Risk Factors of Venous Thromboembolism in Patients Undergoing Systemic Cancer Therapy: A Systematic Review and Meta-Analysis

    S. Lee1, A. Shenoy1, M. Husien2, D. Shi3, S. Parpia4,5, P. Serrano1

  • Abstract Number: PB2120

    Risk Factors, Mortality and Costs of Cancer-Associated Thrombosis in Hospitalised Patients

    W.Y. Jen1, E. Santoso2, S. Kumari2, Y.L. Chee1

  • Abstract Number: PB1810

    Risk Factors, Outcomes, and Score Models of Serious Pulmonary Infection in Non-Splenectomized Immune Thrombocytopenia Adults

    Y. Wu1,2,3, P. Zhao1,2,3, H. Fu1,2,3, J. Zhang1,2,3, Z. Zhang1,2,3, Q. Huang1,2,3, Q. Zeng1,2,3, Y. He1,2,3, X. Wang1,2,3, H. Liu1,2,3, Q. Jiang1,2,3, H. Jiang1,2,3, J. Lu1,2,3, Y. Chang1,2,3, L. Xu1,2,3, X. Huang1,2,3, X. Zhang1,2,3

  • Abstract Number: PB2127

    Risk of Arterial Thromboembolism in Cancer Patients: A Population-Based Cohort Study

    F. Mulder1,2, E. Horváth-Puhó2, N. van Es1, L. Pedersen2, H.R. Büller1, H.E. Bøtker3, H.T. Sørensen2

  • Abstract Number: PB2415

    Risk of Bleeding of Concomitant Antiplatelet and Anticoagulation Therapy in Patient Treated for a Venous Thormboembolic Event

    A. Fayol1, M. Giraud2, L. Plaisance3, L. Bertoletti4, I. Mahé3

  • Abstract Number: PB2474

    Risk of Intracranial Bleeding in Patients with Primary Brain Cancer Receiving Therapeutic Anticoagulation for Venous Thromboembolism: A Meta-analysis

    A. Porfidia1, M. Giordano2, C.L. Sturiale1, S. D'Arrigo1, M.P. Donadini3, A. Olivi2, W. Ageno3, R. Pola2

  • Abstract Number: PB2320

    Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism

    H. Jorgensen1, E. Horváth-Puhó2, K. Laugesen2, S. Braekkan1,3, J.-B. Hansen1,4, H.T. Sørensen2

  • Abstract Number: PB2244

    Risk of Recurrence after a First-lifetime Venous Thrombosis: Impact of Inherited Thrombophilia

    M. Belhadj1,2, H. Baccouche1,2, F. Said1,2, M.H. Houman1,2, N. Ben Romdhane1,2

  • Abstract Number: PB2105

    Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial

    A.L. Nayak1,2, A. Zahrai1, R. Mallick1,2, M. Carrier1,2, P. Wells1,2

  • Abstract Number: PB2178

    Risk of Venous Thromboembolism in the Clinical Course of Osteosarcoma

    M. Stals1, F.H.J. Kaptein1, R.E. Evenhuis2, A.J. Gelderblom3, M.V. Huisman1, R.W.D. Noten1, H.H. Versteeg1, M.A.J. Van de Sande2, F.A. Klok1

  • Abstract Number: PB2339

    Risk of Venous Thrombosis in the Elderly: Lifestyle and its Joint Effect with Factor V Leiden and Prothrombin 20210A

    H. Wang1, M. Cushman2, F. Rosendaal1, A. van Hylckama Vlieg1

  • Abstract Number: PB1344

    Risk Stratification for Intracranial Hemorrhage in Adults with Immune Thrombocytopenia: A Retrospective Multicenter Study

    P. Zhao1,2,3, M. Hou4, H.-X. Liu5, R.-B. Huang6, H.-X. Yao7, T. Niu8, M. Jiang9, Y.-Q. Han10, Y. Liu11, J.-D. Hu12, Z.-P. Zhou13, H. Zhou14, L. Qiu15, L.-S. Zhang16, X. Wang17, H.-Q. Wang18, R. Feng19, L.-H. Yang20, J. Sun21, X.-H. Zhang1,2,3

  • Abstract Number: PB2101

    Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review

    M. Laureano1, L. Goodliffe1, T. Barbui2, D. Chu1, A. Ferrari2, D. Siegal1

  • Abstract Number: PB2563

    Rituximab before Pregnancy in Refractory Obstetrical Antiphospholipid Syndrome

    A. Ciavarella, F. Gianniello, A. Artoni, M. Capecchi, P. Bucciarelli, F. Peyvandi, I. Martinelli

  • Abstract Number: PB1860

    Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan

    M. Kubo1, K. Sakai1, Y. Yoshii2, M. Hayakawa1, M. Matsumoto1

  • Abstract Number: PB0639

    Rivaroxaban 20 mg Oce Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours

    J. Kvasnicka1, Z. Krska2, I. Malikova3, T. Kvasnicka1

  • Abstract Number: PB2391

    Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older

    W. Ageno1, R.D. Lopes2, M. Goldin3, R. Yusen4, G.W. Albers5, C.G. Elliott6, J.L. Halperin7, W.R. Hiatt8, G. Maynard9, P.G. Steg10, J.I. Weitz11, E.Y. Suh12, W. Lu12, E.S. Barnathan12, G.E. Raskob13, A.C. Spyropoulos3

  • Abstract Number: PB0612

    Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study

    J. Arjakse1, R.E. Malmström2,3, L. Gustafsson2, H. Ilumets4, J. Kostjuk4, M. Märk4, M. Pikta5,6, A. Pohanka2,7,8, Y. Rönquist2, T. Marandi9,10

  • Abstract Number: PB2393

    Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial

    A.C. Spyropoulos1, E.S. Barnathan2, W. Ageno3, G.W. Albers4, C.G. Elliott5, W.R. Hiatt6, J.L. Halperin7, G. Maynard8, P.G. Steg9, J.I. Weitz10, T.E. Spiro11, G.E. Raskob12

  • Abstract Number: PB0167

    Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1

    T. Petzold1, M. Thienel1, L. Dannenberg2, P. Mourikis2, C. Helten2, R. M'Pembele2, K. Trojovsky2, Z. Zhang1, R. Regenauer1, J. Pircher1, A. Ehrlich1, E. Lüsebrink1, L. Nicolai1, T. Stocker1, R. Brandl3, F. Röschenthaler4, J. Strecker1, T. Hohlfeld5, M. Kelm2, A. Polzin2

  • Abstract Number: PB2420

    Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients

    O.S. Costa1,2, J. Beyer-Westendorf3, V. Ashton4, D. Milentijevic4, K.T. Moore5, T.J. Bunz6, C.I. Coleman1,2

  • Abstract Number: PB0477

    RMean Platelet Volume to Lymphocyte Ratio and VTE Recurrence

    A.C. Pizzarossa, S. Álvarez, F. Arévalo, C. Arocena, S. Gurruchaga, I. Gutiérrez, A. Pereira, V. Mérola, S. Grille, R. Martínez, C. Guillermo

  • Abstract Number: PB2185

    Role of ADAMTS13, VWF and FVIII in Deep Vein Thrombosis

    M.T. Pagliari1, A. Cairo1, M. Boscarino1, I. Mancini2, E. Pappalardo2, I. Martinelli3, F.R. Rosendaal4, F. Peyvandi1,2

  • Abstract Number: PB1895

    Role of Anti Phosphatidylserine/Prothrombin Antibodies on Thrombin Generation and Protein C Resistance in Carriers of Antiphospholipid Antibodies

    E. Pontara, M. Cattini, E. Bison, C.-Y. Cheng, G. Denas, M. Tonello, V. Pengo

  • Abstract Number: PB1323

    Role of Bone Marrow-Derived Mesenchymal Stem Cell Defects in CD8+ CD28- Suppressor T-Lymphocyte Induction in Patients with Immune Thrombocytopenia and Associated Mechanisms

    H. Li, R. Yang

  • Abstract Number: PB0383

    Role of Endothelial Protein C Receptor Gene Polymorphisms (4678G>C and 6936A>G) in Young Indian DVT Patients

    A. Sharma1, K. Kishor1, A. Biswas2, R. Ranjan1, R. Kumar1, S. Tyagi1, J. Oldenburg2, R. Saxena1, M. Mahapatra1

  • Abstract Number: PB1821

    Role of Formyl Peptide Receptor 2 (FPR2/ALX) and its Anti-Inflammatory Ligand, Lipoxin A4 Analogue (BML-111) in the Modulation of Platelet Function

    S. AlOmar, D. Widera, S. Vaiyapuri

  • Abstract Number: PB1742

    Role of HIF-2α in Promoting Thrombogenicity through PAI-1 Synthesis & EV-Releae during Adaptive Signalling in Human Platelets

    R.L. Mallick1, S.N. Chaurasia2, D. Dash2

  • Abstract Number: PB0188

    Role of Kunitz Domain 3 of Tissue Factor Pathway Inhibitor in Zebrafish

    R. Raman, M. Ryon, A. Al Qaryoute, P. Jagadeeswaran

  • Abstract Number: PB1468

    Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation

    M.L. Guarino1, I. Massimi1, L. Alemanno1, L. Conti2, D.J. Angiolillo3, F.M. Pulcinelli1

  • Abstract Number: PB1617

    Role of Platelet Production/Destruction Imbalance on the Interindividual Variability in Aspirin Response in Diabetic and Non-diabetic Patients

    R. Liani1, P.G. Simeone1, R. Tripaldi1, A. Boccatonda2, D. D'Ardes2, M. Golato3, S. Ciotti1, M. Luongo3, V. Creato1, R. Pepe1, F. Santilli1

  • Abstract Number: PB1825

    Role of Platelets in Processes of Myocardial Healing After Myocardial Ischemia and Reperfusion in Mice

    M. Klier1, A. Ayhan2, L. Dannenberg2, S. Gorressen3, A. Polzin2, M. Elvers2

  • Abstract Number: PB1737

    Role of Receptor for Advanced Glycation End-products (RAGE) in Human Platelets

    D. Recabarren-Leiva1,2, S. Wehinger1,2, E. Fuentes1,2, I. Palomo1,2, M. Alarcón1,2

  • Abstract Number: PB2411

    Role of Residual Pulmonary Vascular Obstruction on the Risk of Long-Term Recurrence of Venous Thromboembolism After Pulmonary Embolism: A Cohort Study

    M.P. Donadini1, F. Boniardi2, F. Dentali1, W. Ageno1

  • Abstract Number: PB1757

    Role of RXRbeta in Platelet Function and Arterial Thrombosis

    E. Lüsebrink1, V. Warm1, J. Pircher1, Z. Zhang1, P. Chambon2, S. Massberg1, C. Schulz1, T. Petzold1

  • Abstract Number: PB0353

    Role of Serpine2 (PN-1) in Diabetic Nephropathy

    L. Idir, K. Aymonnier, Y. Boulaftali, M.-C. Bouton, V. Arocas

  • Abstract Number: PB2575

    Role of Thrombin Generation Potential (TGP) in Cesarean Sections and Vaginal Deliveries Puerperium to Guide Thromboprophylaxis. Preliminary Results

    M. Perez De Palleja1, P. Turcatti2, A. Olivera2, D. Raposo2, C. Canessa2, C. Guillermo3

  • Abstract Number: PB1960

    Role of Thrombopoietin in Rescuing Vascular Niche of ITP Patients

    Y. Jiao, X. Zeng, Z. Li, Y. Zhang, J. Ye

  • Abstract Number: PB1338

    Romiplostim Treatment in Patients with Refractory Inmune Thrombocytopenia Purpura: Experience in a Single Center

    B. Díaz Roldán1, J.F. Domínguez Rodríguez1, L. Martínez Molina2, A.R. Carranco Falcón1

  • Abstract Number: PB0509

    Rotational Thromboelastometry – A Point of Care Tool to Assess Bleeding Risks in Hemophilia A and B

    A. Kholmukhamedov1, B. Benhar1, B. Chea1, R. Al Sawad1, M. Schwaiger1, R. Bottenus1, A. Winkler2

  • Abstract Number: PB2537

    Rotational Thromboelastometry (ROTEM) in Obstetric Population

    B. Grand1, M. Gonzalez Alcantara1, D. Estevez2, L. Voto1

  • Abstract Number: PB0281

    ROTEM Parameters As Bleeding Predictors In Pediatric Cardiac Surgery With Cardiopulmonary Bypass

    D. Truong-Pham1, T. Nguyen1, S. Beaupha1,2, T. Tran1, T. Lai1,2, T. Nguyen1, P. Le-Thanh3, L.-X. Pham-Thi3, V. Le-Thanh4, P. Sa1, D. Nguyen1, T.-T. Nguyen1

  • Abstract Number: PB0315

    Routine Coagulation Assays for the Detection of Residual NOAC Levels in Patients Undergoing Elective Invasive Procedures

    T. Vanassche1, N. Li2, M. Coppens3, A. Spyropoulos4, S. Schulman2, S. Syed5, E. Arnaoutoglou6, J.D. Douketis2

  • Abstract Number: PB0792

    Rutin and Rutin Succinate Improve Murine Survival in an Experimental Model of Acute Hemostatic Disturbances

    A.T.A. Sachetto1, A.O. de Souza2, M.L. Santoro1

Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2021 John Wiley & Sons, Inc. All Rights Reserved.
Wiley
This site uses cookies: Find out more.